Not provided
Not provided
Not provided
Not provided
Recruitment problem
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Teeth with furcation grade II defects will be treated with open flap debridement and regenerative therapy with biphasic calcium phosphate combined with either enamel matrix proteins or a collagen membrane.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Regenerative therapy w/BCP and collagen membrane | Experimental | In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane. |
|
| Regenerative therapy w/BCP and enamel matrix proteins | Active Comparator | In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) | Device | Regenerative therapy with biphasic calcium phosphate + collagen membrane. |
| Measure | Description | Time Frame |
|---|---|---|
| Change of furcation grade level | Proportion of sites demonstrating improvement in furcation grade level as measured with Nabers probe | 12 months after treatment |
| Change of furcation grade level | Proportion of sites demonstrating improvement in furcation grade level as measured with Nabers probe | 24 months after treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in patient-reported quality of life (QoL) | To assess QoL changes related to mouth and teeth prior to therapy to after therapy by the use of "The Oral Impacts on Daily Performance (OIDP)" instrument. Each question is assessed by a 5-point scale; (1) never affected, (2) less than once a month, (3) once or twice a month, (4) once or twice a week; and (5) every or nearly every day. The higher number represents more severe impact on quality of life; e.g. worse outcome. Each item will be dichotomised yielding the categories (A) affected; including scale categories (2)-(5), and (B) unaffected, including category (1). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
The following must not be present at the time of enrolment;
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute of Clinical Dentistry, Faculty of Dentistry, University of Oslo | Oslo | 0455 | Norway |
Not provided
| ID | Term |
|---|---|
| D017823 | Furcation Defects |
| D010510 | Periodontal Diseases |
| ID | Term |
|---|---|
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C074950 | hydroxyapatite-beta tricalcium phosphate |
| C109069 | enamel matrix proteins |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) | Drug | Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins. |
|
| Preoperatively compared to 24 months after treatment |
| Changes in patient-reported quality of life (QoL) | To assess QoL changes related to mouth and teeth prior to therapy to after therapy by the use of "The Oral Impacts on Daily Performance (OIDP)" instrument. Each question is assessed by a 5-point scale; (1) never affected, (2) less than once a month, (3) once or twice a month, (4) once or twice a week; and (5) every or nearly every day. The higher number represents more severe impact on quality of life; e.g. worse outcome. Each item will be dichotomised yielding the categories (A) affected; including scale categories (2)-(5), and (B) unaffected, including category (1). | Preoperatively compared to 12 months after treatment |
| Changes in defect morphology assessed by CBCT | Cone beam computed tomography will be acquired at baseline, 2 weeks postoperatively and 24 months postoperatively. This outcome measures quantitative morphologic changes in the furcation defects at 24 months | 24 months after treatment |
| Changes in CAL | Changes in clinical attachment level will be measured with a probe in mm | 12 months after treatment |
| Changes in CAL | Changes in clinical attachment level will be measured with a probe in mm | 24 months after treatment |
| Changes in PPD | Changes in pocket probing depth will be measured with a probe in mm | 12 months after treatment |
| Changes in PPD | Changes in pocket probing depth will be measured with a probe in mm | 24 months after treatment |
| Radiographic changes | Standardized intraoral bitewing radiographs will be obtained and compared to baseline radiographs | 12 months after treatment |
| Radiographic changes | Standardized intraoral bitewing radiographs will be obtained and compared to baseline radiographs | 24 months after treatment |
| Pain following surgery | Pain sensation for one week posteoperatively will be recorded on a visual analog scale scale from 0-10. 0 is equivalent to no pain, whereas 10 is the highest pain imagineable. | Daily for 1 week postoperatively |
| Caries assessment | Caries in furcation defect assessed with an explorer will be recorded as (Y/N) | 12 months |
| Caries assessment | Caries in furcation defect assessed with an explorer will be recorded as (Y/N) | 24 months |